After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...